Innovative Medicines

Made up of two business units – Novartis Pharmaceuticals and Novartis Oncology – our Innovative Medicines efforts, research, develop and commercialize innovative medicines to enhance health outcomes for patients and HCPs.

Partnering tabs - Therapy Areas

Novartis is uniquely diversified across therapy areas with exposure to cutting-edge technology platforms. We have arguably the richest and broadest pipeline in the industry with more than 65 New Molecular Entities in development. Please select your therapy area of interest to connect to one of our specialist, partnering professionals.

A - G

Seeking transformative immune-regulating or tolerance-inducing approaches to rebuild the immune system.

Enrico Funhoff portrait

Rico Funhoff

Contact me for partnerships before clinical PoC.

Contact

Interested in disruptive technologies and novel treatments addressing heart failure, cardiac arrhythmias and atherosclerosis.

Avi Spier portrait

 

Avi Spier

Contact me for partnerships before clinical PoC.

Contact

Mireia Gomez Angelats portrait

Mireia Gomez Angelats

Contact me for partnerships after clinical PoC.

Contact

Seeking first in class and well differentiated/ best in class treatments for moderate-severe Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Vitiligo, Alopecia Areata and severe forms of Acne as well as curative treatments for rare skin diseases.

Enrico Funhoff portrait

 

Rico Funhoff

Contact me for partnerships before clinical PoC.

Contact

Blue icon of a business man

Patrick Mueller

Contact me for partnerships after clinical PoC.

Contact

Seeking transformative approaches to address genetic diseases.

Leah Bloom portrait

Leah Bloom

Senior Vice President and Head of Novartis Gene Therapies’ External Innovation and Strategic Alliances Tea

Contact me for strategic alliances

 

Blue icon of a business man

 

Blake Arnold

Senior Director, Corporate Development (leads late-stage BD).

Contact me for late stage partnerships

Adam Simpson portrait

Adam Simpson

Senior Director, Business Development (leads early-stage BD).

Contact me for early stage partnerships

 

Blue icon of a business woman

 

Liz Hines

Senior Manager, External Innovation (supports late-stage BD and other external innovation initiatives).

Contact me for early stage partnerships

Blue icon of a business woman

Elizabeth McMath

Associate Director, Global Search & Evaluation

Contact me for late stage partnerships

H - N

Seeking new Mechanisms of Action and combination therapy partners for treating NASH and other non-viral liver diseases or promoting liver regeneration.

Bose Avirup portrait

 

Avirup Bose

Contact me for partnerships before clinical PoC.

Contact

Blue icon of a business man

Partick Mueller

Contact me for partnerships after clinical PoC.

Contact

Interested in disease modifying therapies and disruptive platforms, including cell and gene based therapies, especially for obesity-driven diseases.

Avi Spier portrait

 

Avi Spier

Contact me for partnerships before clinical PoC.

Contact

Mireia Gomez Angelats portrait

Mireia Gomez Angelats

Contact me for partnerships after clinical PoC.

Contact

Seeking truly disease modifying treatments for OA which improve structure, function and pain as well as regenerative therapies for tendon diseases.

Dominic Ehrismann portrait

 

Dominic Ehrismann

Contact me for partnerships before clinical PoC.

Contact

Blue icon of a business man

Patrick Mueller

Contact me for partnerships after clinical PoC.

Contact

Interested in targets for the underlying disease pathology in neurodegenerative diseases, advanced therapeutic options in refractory psychiatric disorders and take to heart pediatric neurological and neuromuscular diseases.

Blue icon of a business woman

 

ChiChi Zhu

Contact me for partnerships before clinical PoC.

Contact

Blue icon of a business woman

Emanuela Basaldella

Contact me for partnerships after clinical PoC.

Contact

O - R

We develop and deliver life-changing medicines for diseases and conditions from front to back of the eye, enabled by data, transformative technologies and partnerships. Our ophthalmic products reach more than 150M people each year, from preterm infants to the elderly.

Adam Feire portrait

 

Adam Feire

Contact me for partnerships before clinical PoC.

Contact

Blue icon of a business man

Dimitrios Lizos

Contact me for partnerships after clinical PoC.

Contact

Interested in renal mechanisms and indications with limited SOC and high unmet need.

Bose Avirup portrait

 

Avirup Bose

Contact me for partnerships before clinical PoC.

Contact

Mireia Gomez Angelats portrait

Mireia Gomez Angelats

Contact me for partnerships after clinical PoC.

Contact

We are looking for partners to expand our portfolio with innovative and potentially transformative agents with a primary focus in Asthma, COPD, IPF, life threatening hospital conditions, food allergy as well as digital solutions to address unmet need in asthma and COPD.

Dominic Ehrismann portrait

 

Dominic Ehrismann

Contact me for partnerships before clinical PoC.

Contact

Blue icon of a business man

Ken Shaw

Contact me for partnerships after clinical PoC.

Contact

Seeking projects with First in Class or Best in Class potential for moderate-severe Rheumatoid & Psoriatic Arthritis, Ankylosing Spondylitis, primary Sjoegren and Lupus with emphasis on oral treatments at par with biologics, or biologics with clear differentiation versus standard of care.

Enrico Funhoff portrait

 

Rico Funhoff

Contact me for partnerships before clinical PoC.

Contact

Blue icon of a business man

Patrick Mueller

Contact me for partnerships after clinical PoC.

Contact

S - Z

Seeking next generation therapies to prevent solid organs rejection, and extend graft life.

Enrico Funhoff portrait

 

Rico Funhoff

Contact me for partnerships before clinical PoC.

Contact

Blue icon of a business man

Patrick Mueller

Contact me for partnerships after clinical PoC.

Contact

We accept that innovation happens outside of areas of interest- we are still prepared to discuss transformational areas we may have missed. We have a special team for you to talk with.

Oncology - Partnering tab

Novartis Oncology seeks partnering opportunities that complement our current portfolio and bring to cancer patients therapies that address needs not fully met by currently available treatments. Such opportunities may be agents targeted to specific biomarkers or other unique mechanisms.

For Radioligand or Precision Medicines partnerships please go to "Platform Collaborations"

Oncology

Our partnering teams are organized by stage of development (clinical stage or early) tumour type, or biology of the intervention - We explore opportunities in areas where Novartis has active efforts, such as breast and lung cancers, melanoma, renal cell carcinoma, and malignant hematology; and we seek to expand into other high-unmet need areas such as hepatocellular, pancreatic, colorectal, and prostate cancers and others.

Mark Temples portrait

Mark Temples

Breast and Gynaecological (Ovarian, Endometrial).

Contact

 

Blue icon of a business woman

 

Lung and Melanoma.

Contact

Blue icon of a business man

Solid Tumours GI/GU.

Contact

 


Hematology

Seeking partners to significantly improve standard of care and cure patients in selected high unmet need in benign hematology diseases. The vision is to transform a number of disease specific classes not limited to hemophilia, complement disorders, anemia, sickle cell disease and thalassemia.

Laura Ripin portrait

Laura Ripin

Leukaemias and Myeloid Dysplastic Syndromes.

Contact

 

Blue icon of a business man

Markus Werner

Lymphomas and Multiple myelomas, CAR-T programs.

Contact

Michael Woo portrait

Michael Woo

ImmunoOncology, CAR-T and Biologics for Oncology.

Contact

 

Reza Mazhari portrait

Reza Mazhari

Small molecules for Oncology.

Contact

 

Bose Avirup portrait

Avirup Bose

Non Malignant Hemotology (Sickle Cell Disease).

Contact

Platform Collaborations - Partnering tab

We are a pioneer in targeted Radioligand therapy and precision Radioligand imaging. Our goal is to transform patients’ lives by leading innovation in nuclear medicine and by investing in targeted Radioligand Therapy to treat advanced cancer – including advanced prostate cancer.

We are interested in partnerships that allow us to:

  • Innovate around targets and vectors- Identify or characterise new targets and receptor types specific to tumour cells or microenvironment.
  • Innovate or access New Chelators, Linkers and Ligands, Develop New Therapeutic or Diagnostic Isotopes or Leverage our developed supply and distribution network.

 

Blue icon of a business man

David Benathan

Contact

 

Mar Murillo portrait

Mar Murillo

Contact

 

Alberto Villena portrait

Alberto Villena

Contact

Novartis is interested in biomarker and diagnostic technologies that are designed to optimize the efficiency, safety and therapeutic benefit of our drugs. Technologies may include genomic and proteomic testing as well as artificial intelligence driven solutions.

Jennifer Leeds portrait

Jen Leeds

Contact me for partnerships before clinical PoC.

Contact

 

Guy Greiveldinger portrait

Guy Greiveldinger

Contact me for partnerships after clinical PoC.

Contact

Novartis Global Health works with partners such as NGOs, academic institutions and companies to expand and accelerate our portfolio of drugs for neglected diseases, including tropical infectious diseases.


Charles Bailey

Charles Bailey

Contact me for partnerships.

Contact